Lexaria Bioscience (LEXX) EBIT Margin (2017 - 2025)
Historic EBIT Margin for Lexaria Bioscience (LEXX) over the last 12 years, with Q3 2025 value amounting to 1545.17%.
- Lexaria Bioscience's EBIT Margin rose 10775200.0% to 1545.17% in Q3 2025 from the same period last year, while for Nov 2025 it was 2062.0%, marking a year-over-year decrease of 5920200.0%. This contributed to the annual value of 1683.01% for FY2025, which is 4438500.0% down from last year.
- According to the latest figures from Q3 2025, Lexaria Bioscience's EBIT Margin is 1545.17%, which was up 10775200.0% from 2155.41% recorded in Q2 2025.
- Lexaria Bioscience's EBIT Margin's 5-year high stood at 460.69% during Q1 2024, with a 5-year trough of 14434.31% in Q4 2021.
- Over the past 5 years, Lexaria Bioscience's median EBIT Margin value was 1904.81% (recorded in 2024), while the average stood at 2878.15%.
- In the last 5 years, Lexaria Bioscience's EBIT Margin tumbled by -141931100bps in 2021 and then soared by 126996000bps in 2022.
- Lexaria Bioscience's EBIT Margin (Quarter) stood at 14434.31% in 2021, then surged by 88bps to 1734.71% in 2022, then soared by 57bps to 753.01% in 2023, then crashed by -94bps to 1462.95% in 2024, then fell by -6bps to 1545.17% in 2025.
- Its last three reported values are 1545.17% in Q3 2025, 2155.41% for Q2 2025, and 1581.04% during Q1 2025.